In addition, amlitelimab, by combining with OX40L and blocking its interaction with OX40, has shown rapid improvement in patients with moderate-to-severe AD, with a favorable safety profile, and efficacy was maintained for 6 months after discontinuation, both of which have demonstrated promise for AD treatment. Here, TNFRSF4 is linked to Alzheimer disease.